For the Inventor, By the Inventor

Enter assignee name

Inflarx Gmbh

USPTO Granted Patents = 14

CIPO Patents = 1

EPO Patents = 5

Trademarks = 2

Forward Citations = 63

Loading Chart...

Loading Chart...

8 inventors (with patents filed for the assignee):

Renfeng Guo (14 out of 15 patents)

Niels Christoph Riedemann (12 out of 12 patents)

Beifen Shen (4 out of 7 patents)

4. Yan Li (3 out of 306 patents)

5. Yong Li (2 out of 2 patents)

6. Niels R Riedemann (1 out of 1 patent)

7. Niels Cristoph Riedemann (1 out of 1 patent)

8. Yan Li (1 out of 2 patents)

9. Li Yan (0 patent)

10. Yan Li (0 patent)

11. Shen Beifen (0 patent)

14 patents: Sort by Forward Citations

1. 12697351 - METHOD OF TREATING CONDITIONS, REDUCING AN INFLAMMATORY RESPONSE, OR IMPROVING ORGAN FUNCTION IN A SUBJECT HAVING A CORONA VIRUS INFECTION BY ADMINISTERING AN INHIBITOR OF C5A ACTIVITY (2026-08-04),

2. 12180274 - Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity (2024-12-31),

3. 11999698 - Fused piperidinyl bicyclic and related compounds as modulators of C5a receptor (2024-06-04),

4. 11890349 - Treatment of inflammatory diseases with inhibitors of C5A activity (2024-02-06),

5. 11464868 - Treatment of inflammatory diseases with inhibitors of C5A activity (2022-10-11),

6. 11273225 - Treatment of inflammatory diseases with inhibitors of C5a activity (2022-03-15),

7. 11149009 - Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor (2021-10-19),

8. 10858421 - Inhibitors of C5A for the treatment of viral pneumonia (2020-12-08),

9. 10774136 - Anti-C5a binding moieties with high blocking activity (2020-09-15),

10. 10376595 - Treatment of inflammatory diseases with inhibitors of C5a activity (2019-08-13),

11. 10227397 - Inhibitors of C5a for the treatment of viral pneumonia (2019-03-12),

12. 9458233 - Anti-C5a binding moieties with high blocking activity (2016-10-04),

13. 9073983 - Anti-C5A binding moieties with high blocking activity (2015-07-07),

14. 8802096 - Anti-C5a binding antibodies with high block activity (2014-08-12),

Inflarx GmbH is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for inflammatory diseases. The company's lead product candidate is a monoclonal antibody targeting the complement system to treat various inflammatory conditions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

14 Patents

#28 in Jena

#2,905 in Germany

#42,118 in the World

Inflarx Gmbh

Forward Citations = 63

8 inventors:

Renfeng Guo (14 out of 15 patents)

Niels Christoph Riedemann (12 out of 12 patents)

Beifen Shen (4 out of 7 patents)

4. Yan Li (3 out of 306 patents)

5. Yong Li (2 out of 2 patents)

Please report any incorrect information to [email protected]

Loading…